NBC Securities’s enGene Therapeutics ENGN Stock Holding History

NBC Securities’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-380	Closed	-$1K	–	2800
2025 Q2	$1K	Buy	+380	New	+$1.43K	﹤0.01%	2372

Other funds holding ENGN

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

NBC Securities's ENGN Position: Q3 2025 in Review

NBC Securities sold out of enGene Therapeutics (ENGN) in Q3 2025, closing a stake of 380 shares — an estimated $1K sold.

NBC Securities first reported a position in ENGN in Q2 2025 and held it in 1 quarter. The position peaked at $1K in Q2 2025. 37 funds tracked by Wall St. Rank hold ENGN as of Q3 2025.

NBC Securities reported no remaining enGene Therapeutics position as of Q3 2025 after selling out during the quarter.
NBC Securities sold 380 enGene Therapeutics shares in Q3 2025, an estimated $1K.
NBC Securities first reported a position in enGene Therapeutics in Q2 2025 and held it in 1 quarter.
NBC Securities's enGene Therapeutics position peaked at $1K in Q2 2025.
37 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2025.

Based on NBC Securities's 13F filing for Q3 2025, filed 14 Nov 2025.